Pfizer layoffs: Pharma giant to cut hundreds of jobs in this country to reduce costs

US-based pharmaceutical giant Pfizer is preparing to lay off hundreds of people in Switzerland as part of the company’s multi-year cost-cutting program, the news agency reported. BloombergPeople aware of the development were cited on Wednesday, December 10, 2025.
The pharmaceutical giant plans to reduce its workforce in Switzerland from the current level of 300 to around 70 by the end of 2025, according to the agency’s report. This layoff move is indicative of the company’s plan to lay off more than 200 people by the end of the year as part of its cost-cutting plans.
Pfizer’s layoffs follow a broader downgrade of Pfizer’s internal Swiss unit, the news agency reported, citing people with knowledge of the development.
Pfizer’s growth path
In early December 2025, Sabine Bruckner, head of Pfizer’s Swiss operations, was replaced by Rea Lal, who now heads the company’s operations in a reduced capacity, according to people quoted in the report.
Bruckner took a new position at the pharmaceutical giant. New York-based pharmaceutical giant Pfizer is trying to stay on track for future growth in the wake of the COVID-19 global pandemic. The company’s multi-year cost-cutting program aims to cut $7 billion by 2027.
The company is “organizing and realigning” its resources to reduce complexity in operations, the news agency reported, citing an emailed statement from a company spokesperson.
The company declined to comment on specific layoff figures for layoffs in Switzerland, according to the agency’s report.
The move comes as the company’s business in Switzerland loses its luster for some multinationals as it implements a new corporate tax regime. Pfizer’s layoffs add to the list of pharmaceutical companies reducing their footprint in Switzerland, where pharmaceuticals are the largest export industry.
According to the agency report, in November 2025, Novartis AG announced that it would lay off up to 550 people in Switzerland due to its automation drive.
Shares of Pfizer were trading at $25.48 as of 12:33 a.m. (EDT) on Wednesday’s U.S. stock market session, up 0.57% from $25.33 at the previous market close, according to data collected from MarketWatch.


